Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Featured
EMA backs extending Mounjaro to children with type-2 diabetes
On 11 December 2025 the EMA's CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.
Latest
ADCY4 Atherosclerosis Mouse Study
A laboratory study links endothelial ADCY4 to vascular inflammation and semaglutide effects in cells and mice, not to a new human treatment result.
GLP-1 Drugs and AF in Obesity With CKD
A matched cohort linked GLP-1 receptor agonist use with less one-year atrial fibrillation in non-diabetic adults with obesity and CKD.
GLP-1 Therapies in ESRD: 2026 Meta-Analysis
A 2026 meta-analysis pooled 19 studies and 388 patients with end-stage renal disease, but most treatment-specific estimates concerned semaglutide.
Japan's GLP-1 treatment cap and regain
A prospective Japanese cohort tracked weight before, during and after time-limited semaglutide or tirzepatide treatment.
GLP-1 Weight-Loss Drugs: Trial Review
A 24-trial network meta-analysis ranked obesity medicines, but high heterogeneity and indirect comparisons limit claims of superiority.
Nerve risks after weight loss drugs
A 2026 review links rare peripheral nerve problems with rapid weight loss during semaglutide or tirzepatide treatment.
MASH Trials: Resmetirom and Semaglutide
Two phase 3 trials support resmetirom and semaglutide in MASH, but their separate designs do not establish which treatment works better.
Semaglutide and Smoking in HIV
A cohort study linked semaglutide initiation to lower cigarette use among people with HIV, but it cannot show that the medicine caused the change.
Tirzepatide Injection Route Error
A single tirzepatide case report links accidental intradermal injection with increased adverse events, but cannot measure the risk.
Tirzepatide and TLR2 Inflammation in Mice
A mouse and cell study found tirzepatide reduced selected inflammatory responses after a Western diet. It was not a clinical outcomes trial.
Adolescent GLP 1s: The Muscle Gap
A new perspective uses semaglutide trial data to ask how adolescent GLP 1 care should track muscle, bone, and physical function.
Atypical anorexia after weight loss
A case report links severe restriction after sleeve gastrectomy, semaglutide, and tirzepatide with atypical anorexia nervosa.
Categories
Regulatory news
Agency actions, classification changes, enforcement letters and scheduling decisions across the EU, EEA, UK and US. Sourced to the primary regulator.
Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Expert digest
Credentialed experts on podcasts, in newsletters and at conferences, paraphrased with verbatim quotes, tier-coded for citation rigour.
Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Comparison
Peptide-vs-peptide, country-vs-country, label-vs-grey-market. Methodology disclosed, conclusions tied to primary sources.
Vendor accountability
Counterfeit warnings, supply-chain incidents, Certificates of Analysis read in detail. We do not sell peptides and we do not promote vendors; we hold them to the same evidence bar as everyone else.
Methodology
How we score evidence depth, source recency and safety clarity. Behind-the-scenes editorial decisions. The reasoning, not just the result.
Country deep-dive
Single-country regulatory or market reports. How peptides actually move through Danish customs; what the BfArM said about a specific schedule shift; the German press response to a Mounjaro shortage.